USE OF ANTI-CAIX/CD70 BISPECIFIC CAR T-CELL FACTORIES TO CHANGE THE TUMOR MICROENVIRONMENT, MITIGATE ON-TARGET OFF-TUMOR TOXICITIES, AND ACHIEVE RCC

Dana-Farber Cancer Institute, Inc.

Investigators